The DCRI Imaging Program is at the forefront of imaging clinical research, with Duke Imaging and Radiology faculty and staff authoring national standards for clinical care and research. The program is one of the most respected imaging clinical trials groups in the world, providing experienced oversight and independent management of all imaging for all phases of clinical trials, including multicenter industry trials.
World-class Technology and Innovative Leadership
The DCRI’s Precision Imaging Program is building on its record of success by adding new technologies and capabilities. Pamela S. Douglas, MD, Ursula Geller Professor of Research in Cardiovascular Diseases and Director of DCRI’s Precision Imaging Program, discusses what's in store for the program.
DCRI Imaging Offerings
- Trial design
- Imaging design
- State-of-the-art imaging techniques
- Results interpretation and dissemination
Regulatory and Policy Expertise
- FDA panels and committees
- Submission experience
- National guidelines authorship
- Project management
- Trial setup
- Site image acquisition and analysis
- Reproducibility testing and remediation
- Data quality assurance
- Compliant with all Good Clinical Practices
- Web-based image transfer linked to EDC
- Web-based PACs system for site and sponsor review
- Secure, cloud-based image storage
- State-of-the-art analysis systems
Pamela Douglas, MD, MACC, FASE, FAHA, is the director of the DCRI Imaging Program and the Geller Professor of Research on Cardiovascular Diseases in the Department of Medicine at Duke. A past president of the American College of Cardiology and American Society of Echocardiography, her 30+ years of experience include leading a variety of multicenter industry and NIH trials and authorship of more than 400 peer-reviewed manuscripts. She is renowned for her work in improving the quality of imaging care. In clinical trials, she has led the development and dissemination of national standards for core lab best practices and the appropriate incorporation of imaging results into overall trial analysis.
Melissa Daubert, MD, FACC, FSCCT, is an assistant professor of medicine in the Department of Medicine at Duke and an investigator in the Imaging Program at the DCRI. Dr. Daubert is a multimodality imager and is board-certified and level III-trained in echocardiography, nuclear cardiology, and cardiac computed tomography. Her clinical research is focused on using cardiac imaging to better evaluate and treat patients with heart failure and coronary artery disease. She is actively involved with national professional societies and travels internationally to engage in humanitarian work with the American Society of Echocardiography Foundation.
Sreekanth Vemulapalli, MD, is an instructor of medicine in the Department of Medicine at Duke University Medical Center and an investigator in the Imaging Program at the DCRI. Dr. Vemulapalli is a multimodality imager with expertise in vascular ultrasound as well as level III training in echocardiography and cardiac MRI. His clinical research is focused on structural heart disease and peripheral vascular disease. Dr. Vemulapalli serves as the clinical lead for the national Transcatheter Valve Therapies Registry in structural heart disease and as a member of other American College of Cardiology committees in structural heart disease.
Case Study: Diagnostic Strategy Comparative Effectiveness Trial
Hear Pamela Douglas, MD discuss the PROMISE trial, a Phase IV randomized clinical trial in the diagnostic strategy space comparing the effectiveness of anatomic versus functional testing strategies for the evaluation of chest pain.
The study included 200 sites, 10,000 subjects; more than 14,000 images (Coronary CT angiography, SPECT MPI, stress echo, stress ECG).